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Introduction
Sepsis is the primary cause of death in the intensive care 
unit [1], and more than 35% of patients are admitted with 
sepsis or develop it during their intensive care unit stay. 
Hospital mortality rates are 27%, reaching 54% in the 
case of septic shock [2].
Extracorporeal blood puriﬁ cation therapies have been 
proposed to improve outcomes for patients with sepsis. 
Th ese therapies are based on the principle that removal 
of inﬂ ammatory mediators or bacterial toxins (or both) 
from the blood will favorably modulate the host inﬂ am-
ma tory response. Recently, signiﬁ cant technological pro-
gress has greatly broadened the spectrum of techniques 
available for blood puriﬁ cation. Indeed, promising results 
have been reported with high-volume hemoﬁ ltration 
(HVHF), cascade hemoﬁ ltration, hemoadsorption, plasma-
pheresis, coupled plasma ﬁ ltration adsorption (CPFA), 
high-adsorption hemoﬁ ltration, and high-cutoﬀ  (HCO) 
hemodialysis/hemoﬁ ltration. However, these techniques 
have not entered into mainstream clinical practice 
around the world.
Th is overview has three aims. First, we will report on 
the latest advances in blood puriﬁ cation for sepsis. Th en, 
we will brieﬂ y describe each therapy and explain how 
they work and discuss how they relate to current 
concepts of disease. Finally, we will review the current 
evidence from the medical literature, highlighting the 
most important studies related to each therapy. To select 
articles from medical literature, we conducted a syste-
matic review of the MEDLINE database using PubMed 
with the following search terms: blood puriﬁ cation, high-
volume hemoﬁ ltration, sepsis, hemoadsorption, high-
cutoﬀ  membranes, and coupled plasma ﬁ ltration adsorp-
tion. Th e search included experimental and clinical studies.
Concept of blood purifi cation
Systemic inﬂ ammatory states such as severe sepsis and 
septic shock result in immunologic disturbances with the 
release of numerous inﬂ ammatory mediators. Th e sys-
temic inﬂ ammatory response, though a result of innate 
immunity, can become deleterious when excessive or 
uncontrolled, leading to the development of multi-organ 
failure syndrome and death. At least two mecha nisms are 
identiﬁ ed to explain the potential harmful eﬀ ects of this 
host inﬂ ammatory response: cyto kines have the capacity 
to damage the cells (cytotoxic eﬀ ects) [3], and the 
prolonged release of inﬂ ammatory mediators leads to 
severely impaired immunity [4]. Th is ‘immunoparalysis’ 
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state plays a major role in mortality because it favors 
severe secondary nosocomial infections. Secondary 
infections can be bacterial but also may be related to 
reactivation of dormant viruses [5,6].
Th e overall concept of blood puriﬁ cation is therefore to 
attenuate this overwhelming systemic expression of pro- 
and anti-inﬂ ammatory mediators. Restoration of immune 
homeostasis is thought to be able to improve outcomes 
and survival. Multiple mediators are involved in this 
inﬂ ammatory response [7], but past attempts to modulate 
it by targeting single components have failed, at least at 
the clinical phase [8]. Th us, over time, the blood puri ﬁ -
cation concept and therapies have evolved toward the 
non-speciﬁ c removal of a broad spectrum of inﬂ am-
matory mediators, which can also include microbial toxins.
Recently, a number of theories to explain the eﬀ ects of 
blood puriﬁ cation have been proposed. First, Ronco and 
colleagues [9] hypothesized that eliminating the peaks of 
cytokine blood concentrations during the early phase of 
sepsis could stop the inﬂ ammatory cascade, limit organ 
damage, and consequently decrease the incidence of 
multi-organ failure syndrome. Second, Honoré and 
Matson [10] proposed the ‘threshold immunomodulation 
hypothesis’, postulating that the cytokine removal from 
the blood compartment leads to the removal of cytokines 
located at the tissue level because of an equilibration of 
their concentrations between these two compartments. 
Th is theory explains why numerous studies assessing 
blood puriﬁ cation techniques found an improvement of 
outcomes with no modiﬁ cation of cytokine blood con-
cen trations as cytokines from the tissues replace those 
removed from the blood. Th ird, Di Carlo and Alexander 
[11] proposed the ‘mediator delivery hypothesis’, in which 
HVHF is responsible for an increase of the lymphatic 
ﬂ ow because of the high amounts of crystalloid ﬂ uids 
used for replacement with this technique. Th is leads to a 
signiﬁ cant drag and displacement of inﬂ ammatory 
media tors to the blood compartment, making them 
available for removal [11].
Finally, Peng and colleagues [12] recently suggested 
that blood puriﬁ cation therapies act at the inﬂ ammatory 
cell level to restore the immune function through the 
regulation of monocytes, neutrophils, or even lympho-
cytes. Th is theory is supported by recent studies [13,14]. 
Indeed, it has been reported that polymyxin B hemo-
adsorption could increase the expression of leukocyte 
surface markers such as HLA-DR [13]. Th us, hemo-
adsorption would act as a ‘reprogrammation system’ for 
the leukocytes. However, the mechanism by which hemo-
adsorption stimulates HLA-DR expression remains 
unknown. If this ‘cellular level’ theory with immune 
response restoration is conﬁ rmed, timing indications for 
blood puriﬁ cation would need to be reconsidered since 
optimal timing for initiating a blood puriﬁ cation therapy 
would not be only in the early phase of septic shock as it 
is suggested today. Furthermore, a novel component of 
this hypothesis is that, by removing mediators from the 
plasma in the setting of systemic inﬂ ammation, one can 
restore the concentration gradient from plasma to 
infected tissues [12]. Th is gradient has signiﬁ cant eﬀ ects 
on leukocyte traﬃ  cking and bacterial clearance [14]. 
Th us, the ‘cytokinetic model’ may be more relevant than 
cytotoxic models to explain the association between high 
cytokine levels and mortality (Figure 1).
High-volume hemofi ltration
By increasing plasma water exchanges, HVHF appears to 
be an attractive therapy to remove a signiﬁ cant amount 
of inﬂ ammatory mediators from the plasma. First, these 
circulating molecules are predominately water-soluble 
and convection carries both plasma water and solutes 
across a semi-permeable membrane along a hydrostatic 
pressure gradient. Second, most inﬂ ammatory mediators 
are so-called middle-molecular-weight molecules with a 
wide range of mass (from 5 to 60 kDa) and convection is 
far more eﬀ ective than diﬀ usion in removing middle 
molecules [15,16]. Th ird, depending on their composi-
tion, most hemoﬁ ltration membranes also have some 
adsorptive properties. Th e ultraﬁ ltrate contains the mole-
cules from the plasma which are able to cross the 
membrane (molecular weight below the membrane cut-
oﬀ ), and adsorption allows the removal of some other 
molecules with a molecular weight higher than the 
membrane cutoﬀ .
HVHF is not well deﬁ ned in the medical literature. 
Recently, Honoré and colleagues [17] convened a con sen-
sus conference to clarify the deﬁ nition of HVHF. Th ey 
agreed that HVHF includes continuous high-volume 
treatment of 50 to 70 mL/kg per hour 24 hours a day and 
intermittent HVHF with brief, very-high-volume treat-
ment at 100 to 120 mL/kg per hour for a short period of 4 
to 8  hours, followed by conventional continu ous veno-
venous hemoﬁ ltration (CVVH). Th is latter strategy is 
also called ‘pulse HVHF’ [18]. However, for experts from 
the Acute Dialysis Quality Initiative work group, greater 
than 35  mL/kg per hour is already con sidered HVHF 
[19]. Indeed, given that ‘renal dose’ hemo ﬁ ltration for 
acute kidney injury has been standardized at 25 to 
30  mL/kg per hour (see reference [20] for justiﬁ  cation), 
deﬁ ning HVHF at greater than 35 mL/kg per hour seems 
reasonable.
Many animal studies have been performed to assess 
HVHF, especially in the 1990s, when HVHF was still very 
experimental in humans. Grootendorst and colleagues 
[21] reported an improvement in cardiac performance in 
pigs with endotoxin-induced shock when HVHF was 
applied. Th e authors hypothesized that some vasoactive 
mediators, responsible for the myocardial depression, 
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were removed with HVHF. Even though other authors 
recently suggested a positive eﬀ ect on the myocardial 
mitochondrial dysfunction [22], the pathophysiologic 
explanation of the hemodynamic improvement with 
HVHF remains unclear [23]. In septic dogs, Bellomo and 
colleagues [24] also found that HVHF improved hemo-
dynamic parameters compared with a sham circuit with 
no hemoﬁ lter. Furthermore, some animal studies 
assessed HVHF by looking at ultraﬁ ltrate obtained from 
either healthy donor or septic donor animals and infused 
into a healthy acceptor animal. Th e ability of HVHF to 
remove toxic mediators is suggested when ultraﬁ ltrate 
obtained from septic animals leads to hemodynamic 
distur bances or even death in healthy animals. In a 
prospective randomized controlled study including 65 
septic pigs, Lee and colleagues [25] reported an increase 
survival time in ﬁ ltered animals compared with matched 
non-ﬁ ltered ones. Increments in survival time even 
increased directly with ﬁ ltration fraction. Moreover, 
ultraﬁ ltrate concentrate obtained from septic pigs 
produced death in healthy ones whereas the infusion of 
‘clean’ ultraﬁ ltrate concentrate produced no response.
Numerous human studies have shown beneﬁ cial 
hemodynamic eﬀ ects of HVHF. In a randomized cross-
over study of 11 patients with septic shock and multi-
organ failure, an 8-hour period of HVHF (6 L/hour) was 
associated with a greater reduction in norepinephrine 
requirements in comparison with a similar period of 
CVVH (1 L/hour) [26]. Reduction of vasopressor require-
ments with HVHF was also found more recently in a pilot 
randomized study comparing CVVH at 65 mL/kg per 
hour versus 35 mL/kg per hour in 20 septic shock 
patients with acute kidney injury [27]. Large randomized 
controlled studies of HVHF in septic shock which use 
mortality as the primary outcome are lacking. One such 
study, known as the IVOIRE (High Volume in Intensive 
Care) study, which compares 70 mL/kg per hour versus 
35  mL/kg per hour, is currently ongoing in Europe. 
Although results from this study have not yet been 
released, the investigators have reported that the enroll-
ment process was very slow and therefore the number of 
patients included is likely to be less than 150, making 
conclusions regarding mortality diﬃ  cult to establish. 
Th us, the only available studies regarding mortality have 
Figure 1. The ‘cytokinetic model’. Blood purifi cation therapies increase the cytokine/chemokine concentration gradient from plasma to infected 
tissue by removing those infl ammatory mediators from the blood compartment. Consequently, leukocyte traffi  cking is driven toward the nidus of 
infection, allowing the increase of local bacterial clearance. CPFA, coupled plasma fi ltration adsorption; HVHF, high-volume hemofi ltration.
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relied on comparisons with expected mortality based on 
the patients’ severity scores at admission. Th ough uncon-
trolled, at least six studies have found signiﬁ cant (and 
sometimes spectacular) reductions in mortality rate with 
HVHF compared with predicted mortality [28-33]. 
Honoré and colleagues [29] reported a reduction of the 
mortality rate from 79% (expected mortality based on 
APACHE II [Acute Physiology and Chronic Health 
Evalua tion II] score and SAPS II [Simpliﬁ ed Acute 
Physiology Score II]) to 55%. Several years later, Joannes-
Boyau and colleagues [30] obtained a similar result with a 
predicted 28-day mortality of 70% and an observed 
mortality of 46% in a study assessing the eﬀ ect of 40 to 
60  mL/kg per hour maintained for 96 hours in patients 
with septic shock. In patients without sepsis but with 
systemic inﬂ ammation, the eﬀ ect of HVHF on mortality 
was evaluated in two randomized controlled trials 
[34,35]. In 61 resuscitated cardiac arrest patients, very-
high-volume hemoﬁ ltration (200 mL/kg per hour during 
8 hours) was associated with improved 6-month survival 
and a decreased risk of death from early intractable shock 
[35]. Th e most important recent studies assessing 
mortality with HVHF as a blood puriﬁ cation therapy are 
summarized in Table  1. Unlike HVHF, standard ‘renal 
dose’ continuous renal replacement therapy (CRRT) 
appears to be ineﬀ ective as an immune modulating 
therapy. Like Cole and colleagues [36] in 2002, Payen and 
colleagues [37] found no diﬀ erence (and even a trend 
toward worse outcomes) between septic shock patients 
who did not have acute kidney injury and who underwent 
CVVH (25 mL/kg per hour for a 96-hour period) at the 
early phase of sepsis and those who were managed 
conventionally.
HVHF has important limitations such as a theoretical 
depletion of low-molecular-weight molecules (nutrients, 
vitamins, trace elements, and drugs such as antibiotics), 
an elevated cost due mainly to the requirement of large 
replacement ﬂ uid amounts, and a high nursing workload 
[38,39]. Cascade hemoﬁ ltration was recently developed 
to limit some of these drawbacks [40]. It allows appli-
cation of HVHF select ively on middle-molecular-weight 
molecules with a low replacement ﬂ uid ﬂ ow rate because 
of a particular circuit that combines two hemoﬁ ltration 
membranes having diﬀ erent cutoﬀ s (Figure 2).
Hemoadsorption
Hemoadsorption places sorbents in direct contact with 
blood via an extracorporeal circuit. Th e sorbent attracts 
solutes through hydrophobic interactions, ionic attrac tion, 
hydrogen bonding, and van der Waals interactions [41]. 
Until recently, poor biocompatibility has been the main 
clinical limitation of hemoadsorption, as evidenced by 
severe thrombocytopenia and leukopenia [41]. Th e interest-
ing feature of hemoadsorption is its high-molecular-weight 
adsorption potential, allowing it to target large molecules, 
exceeding the cutoﬀ  of conventional synthetic high-ﬂ ux 
hemoﬁ lters.
Polymyxin B is a cyclic basic polypeptide that disrupts 
the permeability of the cell membrane of Gram-negative 
bacteria. It was developed as an antibiotic but its severe 
renal toxicity precludes systemic use. However, poly-
myxin B-immobilized polystyrene-derived ﬁ bers have 
been developed for use in extracoporeal therapy as a 
means to remove endotoxin from the blood. Th ough still 
under evaluation in Europe and the US, polymyxin B 
hemoadsorption (Toraymyxin; Toray Industries, Inc., 
Tokyo, Japan) is widely used in Japan as a blood puriﬁ -
cation therapy and is covered by the Japanese national 
health insurance [42]. Th e EUPHAS (Early Use of 
Polymyxin B Hemoperfusion in Abdominal Sepsis) study 
was a prospective, multicenter randomized controlled 
study that was performed in 10 Italian intensive care 
units [43]. Sixty-four patients with severe sepsis or septic 
shock were randomly assigned to one of two groups 
(either conventional therapy or conventional therapy 
along with two sessions of polymyxin B hemoadsorption) 
within the 6 hours following emergency surgery for intra-
abdominal infection. Hemodynamics, the PaO2/FiO2 
(arterial partial pressure of oxygen/fraction of inspired 
oxygen) ratio, and the SOFA (Sequential Organ Failure 
Assessment) score of patients from the hemoadsorption 
group improved within 72 hours, whereas the conven-
tional group did not. Th e main result (though not the 
primary outcome) of this study was the 28-day mortality 
rate, which was drastically reduced to 32% in the hemo-
adsorption group compared with 53% in the control 
group (P = 0.03). However, the conclusions of this study 
should be taken with caution. Indeed, although mortality 
was only a secondary endpoint, the study was prema-
turely stopped because it was judged to be unethical to 
deprive patients of hemoadsorption. Th e decision to halt 
the study seems extremely debatable because it was based 
upon a secondary analysis of an underpowered study and 
a diﬀ erent outcome in a single patient would have 
abolished the statistical diﬀ erence in mortality [44]. 
Moreover, the fact that the study was controlled is also 
debatable since hemodynamic and respiratory para-
meters were only analyzed independently within each 
group, comparing 72-hour to baseline levels. No statis-
tical comparison was performed between the two groups 
at 72 hours. No statistical comparison was performed 
between the two groups at 72 hours.
Other trials showed interesting results with polymyxin 
B hemoadsorption. Vincent and colleagues [45] con-
ducted a multicenter randomized controlled study that 
enrolled 36 postsurgical patients with septic shock. Nine-
teen patients were allocated to standard treatment, and 
17 were given an additional polymyxin B hemoadsorption 
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session. Endotoxin and interleukin-6 concentrations were 
not diﬀ erent between the two groups within the 24 hours 
following the start of treatment. However, patients 
treated with hemoadsorption had a marked improvement 
in hemodynamics and oxygen transport function, and the 
need for CRRT after the study was less important in the 
hemoadsorption group. Th ese beneﬁ cial eﬀ ects were also 
reported in a systematic review of 28 publications (1,425 
patients) [46]. Indeed, although Cruz and colleagues [46] 
highlighted the suboptimal quality of the studies, 
favorable eﬀ ects regarding blood pressure, vasopressor 
require ment, gas exchanges, and even mortality were 
Table 1. Summary of recent human studies that assessed the eff ects of high-volume hemofi ltration as a blood 
purifi cation technique on hemodynamics and survival
    Dose,  Improved Improved 
  Number of  mL/kg hemodynamics survival P value
Study Design patients Clinical setting per hour with HVHF with HVHF (survival)
Honoré, et al.  Prospective,  20 Refractory septic 115 Yes Yes.  <0.05
[29] 2000  cohort,   shock   28-day survival: 21% (expected) 
 uncontrolled     to 45% (observed) 
Cole, et al.  Randomized,  11 Septic shock with 6,000 mL/hour Yes Not assessed N/A
[26] 2001  crossover  multi-organ failure
Joannes-Boyau,  Prospective,  24 Septic shock  40-60 Yes Yes.  <0.075
et al. [30] 2004  cohort,      28-day survival: 30% (expected) 
 uncontrolled      to 54% (observed) 
Laurent, et al.  RCT 61 Resuscitated  200 Yes Yes.  0.026
[35] 2005    cardiac arrest   Six-month survival: 21% to 45%
Jiang, et al.  RCT 37 Severe acute  4,000 mL/hour Yes Yes.  <0.01
[34] 2005    pancreatitis   14-day survival: 68.4% to 94.4%
Ratanarat, et al.  Prospective,  15 Severe sepsis 85 (pulse HVHF) Yes Yes.  N/A
[33] 2005  cohort,      28-day survival: 30% (expected) 
 uncontrolled     to 53% (observed)
Piccinni, et al.  Retrospective,  80 Septic shock 45 Yes Yes.  
[32] 2006  uncontrolled     28-day survival: 27.5% to 55% 0.005
Cornejo, et al.  Prospective,  20 Refractory septic 100 Yes Yes.  <0.03
[28] 2006  cohort,   shock   Hospital survival: 37% (expected) 
 uncontrolled     to 60% (observed)  
Boussekey, et al.  RCT 20 Septic shock 65 Yes No 0.65
[27] 2008 
Zhu, et al.  Retrospective 63 Severe acute 60-80 No Yes.  0.014
[77] 2009    pancreatitis   28-day survival: 65.5% to 91.2%
IVOIRE study,  RCT Approximately  Septic shock 70 Not Not Not
ongoing  150   reported reported reported
HVHF, high-volume hemofi ltration; IVOIRE, High Volume in Intensive Care; N/A, not applicable; RCT, randomized controlled trial.
Figure 2. Cascade hemofi ltration circuit.
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reported. Importantly, this review points out the need for 
further rigorous studies of this therapy. Two large 
multicenter studies, similar to the EUPHAS study, were 
expected to be started in the US and Europe in 2010.
Th e CytoSorb™ technology (CytoSorbents Corporation, 
Monmouth Junction, NJ, USA) is composed of cartridges 
containing biocompatible polystyrene divinyl benzene 
copolymer beads. Th is technology does not target 
endotoxin but has been shown to result in rapid in vitro 
and in vivo elimination of several key cytokines [47]. 
Recently, 33 septic rats were randomly assigned to receive 
either hemoadsorption or sham treatment for 3 hours 
[48]. Cytokine concentrations were lower in the hemo-
adsorption group at the end of the treatment and this 
diﬀ erence lasted 6 hours after treatment. Blood pressure 
of the rats from the hemoadsorption group was higher 
than that of the sham group. Finally, the overall survival 
rate (deﬁ ned at 12 hours after randomization) was also 
signiﬁ cantly greater in the hemoadsorption group (11/17 
versus 2/16; P <0.01).
Th e resin referred to by its manufacturer as “CTR 
resin” (Kaneka Corporation, Osaka, Japan) is an adsor-
bent composed of porous cellu lose beads. Taniguchi and 
colleagues [49] reported that CTR eﬀ ectively adsorbed 
small- to middle-sized proteins such as cytokines, entero-
toxins, and toxic shock syn drome toxin-1 in vitro. Addi-
tion ally, in an endotoxemic rat model, hemoadsorption 
with CTR dramatically reduced the mortality rate 8 hours 
after endotoxin injection (14% versus 92% for endo toxe-
mia alone) [49]. Interestingly, the same authors further 
demon strated in rats the dose-related eﬀ ects of 
hemoadsorption with CTR on mortality [50].
Plasmapheresis and coupled plasma fi ltration 
adsorption
Only very limited data are available in the medical litera-
ture regarding plasmapheresis, plasma exchanges, and 
related techniques for this indication [51-55]. Never-
theless, it has been suggested that these therapies might 
be beneﬁ cial, especially for patients with Gram-negative 
sepsis [52,54,56,57] and when implemented as early as 
possible [58]. Additional studies are therefore warranted 
to better assess these therapies for blood puriﬁ cation 
[59].
CPFA ﬁ rst separates plasma from the blood by means 
of a plasma ﬁ lter. Th e plasma then circulates through a 
sorbent, allowing inﬂ ammatory mediator adsorption, and 
ﬁ nally returns to the blood, where a second blood ﬁ lter is 
used for renal support (hemoﬁ ltration, hemodialysis, or 
hemodiaﬁ ltration) (Figure 3). Performing adsorption 
with plasma, rather than with blood, avoids coagulation 
issues, platelet aggregation, and hemolysis and allows the 
use of a low ﬂ ow rate, extending the time of contact 
between the inﬂ ammatory mediators and the sorbent 
and consequently maximizing their adsorption.
Several studies have demonstrated the safety and the 
eﬀ ectiveness of CPFA for removing inﬂ ammatory media-
tors from the circulation [60,61]. Moreover, CPFA was 
able to increase the survival of a rabbit model of endo-
toxic shock and to improve hemodynamics and the 
pulmonary function of patients with septic shock [62,63]. 
Recently, CPFA was compared with other extracorporeal 
blood puriﬁ cation techniques. In a small pilot study, 
Lentini and colleagues [64] reported no diﬀ erence in 
hemodynamic eﬀ ects between pulse HVHF and CPFA in 
patients with septic shock. In pigs with hyperdynamic 
septic shock, continuous hemoﬁ ltration, unlike CPFA, 
was able to remove some inﬂ ammatory mediators 
involved in delayed cardiac repolarization [65]. Con-
versely, Ronco and colleagues [61] reported in patients 
with septic shock that CPFA combined with hemodialysis 
was associated with greater improved hemodynamics 
compared with continuous hemodiaﬁ ltration. Th e 
authors hypothesized that this result could be due to the 
ability of CPFA to restore leukocyte responsiveness to 
lipo polysaccharide. Interestingly, eﬀ ects of CPFA on 
immune function were also shown by Mao and colleagues 
[66] in a small crossover study comparing CPFA with 
HVHF in septic patients with multiple organ dysfunction 
syndrome. HLA-DR expression increased after CPFA but 
Figure 3. Coupled plasma fi ltration adsorption circuit.
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there was no change after HVHF. In addition, spon-
taneous and lipopolysaccharide-induced tumor necrosis 
factor production increased over time with CPFA but did 
not change with HVHF. Th e authors therefore suggested 
that CPFA was superior to HVHF in restoring leukocyte 
responsiveness.
High-adsorption hemofi ltration and high-cutoff  
membranes
Other approaches proposed for blood puriﬁ cation 
therapies consist of optimizing the performances of the 
hemoﬁ lters regarding cytokine or endotoxin removal (or 
both) by manipulating their composition or structure. 
High-adsorption hemoﬁ ltration is a technique whereby 
the adsorption properties of a hemoﬁ lter are enhanced. 
Positive hemodynamic eﬀ ects of a polyacrylonitrile 
hemoﬁ ltration membrane having endotoxin adsorption 
properties were recently reported in septic pigs [67]. Th e 
membrane surface polarity was modiﬁ ed by adjunction 
of a polyethylenimine coating, a positively charged poly-
mer, allowing it to catch negatively charged endotoxins 
via surface adsorption. Th is study highlights another 
potentially important aspect of blood puriﬁ cation for the 
future: the synergy between diﬀ erent blood puriﬁ cation 
mechanisms (HVHF + high adsorption) [67,68]. In the 
same line, other models in which HVHF and high-
permeability hemoﬁ ltration work synergistically have 
shown promising results [69].
Th e use of HCO membranes represents another logical 
strategy to increase mediator removal. When the mem-
brane pore size is increased from 0.01 to 0.02 μm 
(Figure  4), the spectrum of molecules aﬀ ected by the 
therapy is signiﬁ cantly broadened [70]. In experimental 
models of sepsis, HCO membranes improve hemo-
dynamics and prolong survival [71]. In patients with 
sepsis-induced acute kidney injury, Morgera and 
colleagues [72] reported a reduction in vasopressor 
require ments with the use of HCO hemoﬁ ltration and 
not with conventional CVVH. Additionally, cytokine 
clear ance rates were signiﬁ cantly higher in the HCO 
hemo ﬁ ltration group. In another randomized study, 
HCO hemoﬁ ltration restored the monocyte proliferation 
Figure 4. Electronic microscopy images of the internal surface of diff erent fi lters.
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capacity of septic patients, probably by eliminating 
immunomodulatory mediators [73]. However, the use of 
HCO hemoﬁ ltration has been challenged by the albumin 
loss, which can be up to 15 g per 4-hour session [74]. 
Consequently, HCO membranes are now proposed for 
use with hemodialysis. Indeed, the use of diﬀ usion rather 
than convection is suggested to reduce the albumin loss 
without signiﬁ cantly impacting cytokine clearances, 
especially in cases of elevated dialysate ﬂ ow rates [74]. 
Haase and colleagues [75] showed that HCO hemo-
dialysis was more eﬃ  cient than standard hemo dialysis in 
regard to diﬀ usive cytokine clearances. While some 
decreases in plasma cytokine levels were even reported 
after only 4 hours of treatment, the albumin loss was 
limited and plasma albumin concentrations remained 
stable. Conversely, Lee and colleagues [76] recently 
highlighted reductions in serum albumin levels after 
HCO hemodialysis sessions, leaving this question open 
to further clinical investigation. To address this issue, 
membrane parameters and aspects other than the type of 
modality (diﬀ usion versus convection) – for example, 
membrane homogeneity in terms of pore size, membrane 
surface, the use of super-high-ﬂ ux hemoﬁ lters that have a 
slightly lower cutoﬀ , and the use of the association 
HVHF-high permeability – certainly need to be taken 
into account [69]. Finally, it should be mentioned that the 
medical literature regarding HCO membranes contains 
signiﬁ cant heterogeneity due to diﬀ erences in terms of 
type of HCO membrane (cutoﬀ  points, surface area, and 
composition), modality used, and type of cytokines 
measured, making conclusions regarding this strategy 
diﬃ  cult to establish.
Conclusions
Considerable work remains in order to ﬁ nd and optimize 
the best blood puriﬁ cation strategy for treatment of 
sepsis. A better understanding of how these therapies 
work by modulating the cytotoxic and cytokinetic eﬀ ects 
of inﬂ ammatory mediators is essential. Convection, 
diﬀ usion, and adsorption should probably not be seen as 
competitive mechanisms for blood puriﬁ cation but 
rather as complementary ones. Many experimental and 
clinical studies have reported promising results showing 
that blood puriﬁ cation therapies are well tolerated, 
eﬀ ective in clearing inﬂ ammatory mediators or endo-
toxins (or both) from the plasma, and responsible for an 
improvement of diﬀ erent physiologic parameters (hemo-
dynamics and oxygenation). However, important ques-
tions, including timing, duration, and frequency of these 
therapies in the clinical setting, remain unanswered. 
Large multicenter trials evaluating the ability of these 
therapies to improve clinical outcomes (that is, mortality 
or organ failure), rather than focusing on surrogate 
markers such as plasma mediator clearance or transient 
improvement in physiologic variables, are required to 
deﬁ ne the precise role of blood puriﬁ cation in the 
management of sepsis.
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